Literature DB >> 12527815

Anandamide inhibits nuclear factor-kappaB activation through a cannabinoid receptor-independent pathway.

Rocío Sancho1, Marco A Calzado, Vincenzo Di Marzo, Giovanni Appendino, Eduardo Muñoz.   

Abstract

Anandamide (arachidonoylethanolamine, AEA), an endogenous agonist for both the cannabinoid CB(1) receptor and the vanilloid VR1 receptor, elicits neurobehavioral, anti-inflammatory, immunomodulatory, and proapoptotic effects. Because of the central role of nuclear factor-kappaB (NF-kappaB) in the inflammatory process and the immune response, we postulated that AEA might owe some of its effects to the suppression of NF-kappaB. This study shows that AEA inhibits tumor necrosis factor-alpha (TNFalpha)-induced NF-kappaB activation by direct inhibition of the IkappaB kinase (IKK)beta and, to a lesser extent, the IKKalpha subunits of kappaB inhibitor (IkappaB) kinase complex, and that IKKs inhibition by AEA correlates with inhibition of IkappaBalpha degradation, NF-kappaB binding to DNA, and NF-kappaB-dependent transcription in TNFalpha-stimulated cells. AEA also prevents NF-kappaB-dependent reporter gene expression induced by mitogen-activated protein kinase kinase kinase and NF-kappaB-inducing kinase. The NF-kappaB inhibitory activity of AEA was independent of CB(1) and CB(2) activation in TNFalpha-stimulated 5.1 and A549 cell lines, which do not express vanilloid receptor 1, and was not mediated by hydrolytic products formed through the activity of the enzyme fatty acid amide hydrolase. Chemical modification markedly affected AEA inhibitory activity on NF-kappaB, suggesting rather narrow structure-activity relationships and the specific interaction with a molecular target. Substitution of the alkyl moiety with less saturated fatty acids generally reduced or abolished activity. However, replacement of the ethanolamine "head" with a vanillyl group led to potent inhibition of TNFalpha-induced NF-kappaB-dependent transcription. These findings provide new mechanistic insights into the anti-inflammatory and proapoptotic activities of AEA, and should foster the synthesis of improved analogs amenable to pharmaceutical development as anti-inflammatory agents.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12527815     DOI: 10.1124/mol.63.2.429

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  31 in total

1.  WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.

Authors:  David A Price; Alex A Martinez; Alexandre Seillier; Wouter Koek; Yolanda Acosta; Elizabeth Fernandez; Randy Strong; Beat Lutz; Giovanni Marsicano; James L Roberts; Andrea Giuffrida
Journal:  Eur J Neurosci       Date:  2009-05-21       Impact factor: 3.386

Review 2.  Endocannabinoid signalling in innate and adaptive immunity.

Authors:  Valerio Chiurchiù; Luca Battistini; Mauro Maccarrone
Journal:  Immunology       Date:  2015-03       Impact factor: 7.397

3.  A role for the anandamide membrane transporter in TRPV1-mediated neurosecretion from trigeminal sensory neurons.

Authors:  Theodore J Price; Amol M Patwardhan; Christopher M Flores; Kenneth M Hargreaves
Journal:  Neuropharmacology       Date:  2005-04-01       Impact factor: 5.250

Review 4.  Do cannabinoids have a therapeutic role in transplantation?

Authors:  Mitzi Nagarkatti; Sadiye Amcaoglu Rieder; Venkatesh L Hegde; Shunsuke Kanada; Prakash Nagarkatti
Journal:  Trends Pharmacol Sci       Date:  2010-06-28       Impact factor: 14.819

5.  AM404, an inhibitor of anandamide uptake, prevents pain behaviour and modulates cytokine and apoptotic pathways in a rat model of neuropathic pain.

Authors:  Barbara Costa; Dario Siniscalco; Anna Elisa Trovato; Francesca Comelli; Maria Luisa Sotgiu; Mariapia Colleoni; Sabatino Maione; Francesco Rossi; Gabriella Giagnoni
Journal:  Br J Pharmacol       Date:  2006-06-12       Impact factor: 8.739

6.  2-Arachidonoylglycerol stimulates activator protein-1-dependent transcriptional activity and enhances epidermal growth factor-induced cell transformation in JB6 P+ cells.

Authors:  Qing Zhao; Zhiwei He; Nanyue Chen; Yong-Yeon Cho; Feng Zhu; Chengrong Lu; Wei-Ya Ma; Ann M Bode; Zigang Dong
Journal:  J Biol Chem       Date:  2005-05-10       Impact factor: 5.157

7.  Rimonabant (SR141716) exerts anti-proliferative and immunomodulatory effects in human peripheral blood mononuclear cells.

Authors:  A M Malfitano; C Laezza; S Pisanti; P Gazzerro; M Bifulco
Journal:  Br J Pharmacol       Date:  2007-12-24       Impact factor: 8.739

Review 8.  Endocannabinoids and traumatic brain injury.

Authors:  R Mechoulam; E Shohami
Journal:  Mol Neurobiol       Date:  2007-09-18       Impact factor: 5.590

Review 9.  The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain.

Authors:  Giulia Donvito; Sara R Nass; Jenny L Wilkerson; Zachary A Curry; Lesley D Schurman; Steven G Kinsey; Aron H Lichtman
Journal:  Neuropsychopharmacology       Date:  2017-08-31       Impact factor: 7.853

Review 10.  The endocannabinoid system in pain and inflammation: Its relevance to rheumatic disease.

Authors:  Nicola Barrie; Nicholas Manolios
Journal:  Eur J Rheumatol       Date:  2017-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.